Location Directory

Clinical trials in Aurora, Colorado

This page shows live ClinicalTrials.gov search results for Aurora, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7450

Shown on this page

Current sort

Institutions in Aurora

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

University of Colorado Anschutz

Live official records

Open in full search

Conditions: Tumours, Gynecological
Interventions: Mo-Rez, Dostarlimab, Bevacizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: La Jolla, California • Aurora, Colorado • Rochester, New York + 2 more

Conditions: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy, Dystrophinopathy, Dystrophinopathy Symptomatic Female Carrier
Interventions: Observational study with patients who may be treated with various disease-modifying therapies; Other
Lead sponsor: The Duchenne Registry; Other
Eligibility: Not listed
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2072
U.S. locations: 11
States / cities: Little Rock, Arkansas • Sacramento, California • Aurora, Colorado + 7 more

Conditions: Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
Interventions: Capecitabine, Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Temozolomide; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 673
States / cities: Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more

Conditions: Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 815
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 511 more

Conditions: Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Interventions: ALLO-329, Cyclophosphamide, Fludarabine; Genetic · Drug
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 17
States / cities: Phoenix, Arizona • Loma Linda, California • Aurora, Colorado + 14 more

Conditions: Focal Epilepsy, Tonic-Clonic Seizures
Interventions: XEN1101; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 54
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 48 more

Conditions: Systemic Lupus Erythematosus
Interventions: DZP, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 16 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 63
States / cities: Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 55 more

Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Interventions: Casdatifan, Cabozantinib, Placebo; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 46
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 40 more

Conditions: Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations
Interventions: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice; Drug
Lead sponsor: ArriVent BioPharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 21
States / cities: Fullerton, California • Los Angeles, California • Orange, California + 17 more

Conditions: Tachyarrhythmia
Interventions: defibrillation lead; Device
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 64
States / cities: Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 56 more

Conditions: Glioblastoma
Interventions: Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine; Drug · Radiation · Biological
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years and older
Enrollment: 2,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 42
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more

Conditions: Parkinsons Disease (PD)
Interventions: bemdaneprocel, Sham surgery; Biological · Procedure
Lead sponsor: BlueRock Therapeutics; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 34
States / cities: Scottsdale, Arizona • Sun City, Arizona • Little Rock, Arkansas + 27 more

Clinical trials in Aurora, Colorado

Filter and sort this location

Institutions in Aurora

Live official records

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

Duchenne Electronic Health Record Study

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

An Open-label Study of XEN1101 in Epilepsy

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Lead Evaluation for Defibrillation and Reliability Post Approval Study

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease